Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
Public ClinicalTrials.gov record NCT02833350. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response or Intolerance to Previous TNF Therapy (Cohort 2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to severe active RA and an inadequate response to previous methotrexate (MTX) therapy (Cohort 1) or MTX and tumor necrosis factor (TNF) therapy who may have also had exposure to no more than one non-TNF inhibitor biologic (Cohort 2).
Study identification
- NCT ID
- NCT02833350
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 578 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 8, 2016
- Primary completion
- Jul 1, 2018
- Completion
- Jul 1, 2018
- Last update posted
- Jun 11, 2020
2016 – 2018
United States locations
- U.S. sites
- 23
- U.S. states
- 10
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Research Group; Llc, Central | Anniston | Alabama | 36207 | — |
| Arizona Arthritis & Rheumatology Associates, P.C. | Glendale | Arizona | 85306 | — |
| Medvin Clinical Research | Covina | California | 91723 | — |
| TriWest Research Associates, LLC | El Cajon | California | 92020 | — |
| Saint Jude Heritage Medical Grp | Fullerton | California | 92835 | — |
| Stanford University School of Medicine | Stanford | California | 94305-5151 | — |
| RASF-Clinical Research Center | Boca Raton | Florida | 33486 | — |
| ZASA Clinical Research | Boynton Beach | Florida | 33472 | — |
| Clinical Research of West Florida | Clearwater | Florida | 33765 | — |
| InVentiv Health | Miami | Florida | 33136 | — |
| Omega Research Consultants | Orlando | Florida | 32810 | — |
| McIlwain Medical Group | Tampa | Florida | 33613 | — |
| Institute of Arthritis Research | Idaho Falls | Idaho | 83404 | — |
| Advanced Clinical Research | Meridian | Idaho | 83642 | — |
| Medication Management | Greensboro | North Carolina | 27408 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Clinical Research Center of Reading | Wyomissing | Pennsylvania | 19610 | — |
| Metroplex Clinical Research | Dallas | Texas | 75231 | — |
| Baylor Research Inst. | Dallas | Texas | 75246 | — |
| Accurate Clinical Management - VO | Houston | Texas | 77004 | — |
| Accurate Clinical Research | Houston | Texas | 77089 | — |
| Crossroads Clinical Research, LLC | Victoria | Texas | 77901 | — |
| Danville Orthopedic Clinic, Inc.; Research Department | Danville | Virginia | 24541 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 127 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02833350, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2020 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02833350 live on ClinicalTrials.gov.